Home  »  Business   »  Prometheus Biosciences Inc. (RXDX) Reveals an Earn...

Prometheus Biosciences Inc. (RXDX) Reveals an Earnings Mystery

Prometheus Biosciences Inc. (NASDAQ:RXDX) went down by -6.53% from its latest closing price compared to the recent 1-year high of $63.13. The company’s stock price has collected -8.78% of loss in the last five trading sessions.

Is It Worth Investing in Prometheus Biosciences Inc. (NASDAQ :RXDX) Right Now?

Opinions of the stock are interesting as 11 analysts out of 11 who provided ratings for Prometheus Biosciences Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 0 rated it as “hold,” and 0 as “sell.”

Do You Own These 7 Inflation-Survival Stocks?

Inflation is still near 40-year highs and rising prices are putting a big dent in our wallets. Unless you find out how to protect your portfolio and outpace inflation, you'll keep being at the mercy of economic factors out of your control. Especially since the price of electricity, food, and shelter are creeping up higher than ever. In this special report, I detail 7 stocks to help you survive and thrive in today's market. They're backed by solid companies, positioned to profit during tough economic times, and offer out-sized dividends to help you outpace inflation.

Click here to get your free copy of the report


The average price from analysts is $64.18, which is $21.07 above the current price. RXDX currently public float of 32.92M and currently shorts hold a 13.70% ratio of that float. Today, the average trading volume of RXDX was 557.81K shares.

RXDX’s Market Performance

RXDX stocks went down by -8.78% for the week, with a monthly drop of -16.52% and a quarterly performance of -14.63%, while its annual performance rate touched 54.13%. The volatility ratio for the week stands at 5.92% while the volatility levels for the past 30 days are set at 6.85% for Prometheus Biosciences Inc. The simple moving average for the period of the last 20 days is -12.53% for RXDX stocks with a simple moving average of 5.48% for the last 200 days.

Analysts’ Opinion of RXDX

Many brokerage firms have already submitted their reports for RXDX stocks, with Goldman repeating the rating for RXDX by listing it as a “Buy.” The predicted price for RXDX in the upcoming period, according to Goldman is $51 based on the research report published on July 20th of the current year 2022.

Piper Sandler, on the other hand, stated in their research note that they expect to see RXDX reach a price target of $53. The rating they have provided for RXDX stocks is “Overweight” according to the report published on June 10th, 2022.

BTIG Research gave a rating of “Buy” to RXDX, setting the target price at $62 in the report published on February 11th of the current year.

RXDX Trading at -16.62% from the 50-Day Moving Average

After a stumble in the market that brought RXDX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -31.71% of loss for the given period.

Volatility was left at 6.85%, however, over the last 30 days, the volatility rate increased by 5.92%, as shares sank -16.89% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -24.71% lower at present.

During the last 5 trading sessions, RXDX fell by -8.78%, which changed the moving average for the period of 200-days by +13.15% in comparison to the 20-day moving average, which settled at $48.85. In addition, Prometheus Biosciences Inc. saw 9.03% in overturn over a single year, with a tendency to cut further gains.

Stock Fundamentals for RXDX

Current profitability levels for the company are sitting at:

  • -2806.10 for the present operating margin
  • +91.75 for the gross margin

The net margin for Prometheus Biosciences Inc. stands at -2882.55. Equity return is now at value -61.40, with -50.30 for asset returns.

The liquidity ratio also appears to be rather interesting for investors as it stands at 16.14.